Laekna, Inc. (HK:2105) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Laekna, Inc. has announced the initiation of an IND-enabling study for LAE123, a monoclonal antibody aimed at treating severe diseases such as pulmonary arterial hypertension and spinal muscular atrophy. This advancement highlights LAE123’s potential in blocking ActRIIA/IIB signaling, which is implicated in various severe health conditions. Investors in the pharmaceutical sector may find this development promising as Laekna continues its research efforts.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Here Is a Look into the Boeing (NYSE:BA) Contract Offers That Ended Its Strike
- What If Elon Musk Actually Did Buy the Comcast (NASDAQ:CMCSA) Channels?
- Long John Silver: Pirate, Mutineer, and Personal Finance Guru?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
